Prosecution Insights
Last updated: August 08, 2026

Vrije Universiteit Brussel

9 pending office actions • 8 art units • 9 examiners • 0 of 9 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days

Portfolio Summary

9
Total Pending OAs
8
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
1
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Due ≤ 30 days (1)Due ≤ 60 days (1)Due later (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (33%)
5
Medium (56%)
1
Easy (11%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§101 + other1 (11%)
§103 only3 (33%)
§102 only1 (11%)
§112 only1 (11%)
Double-patenting + other1 (11%)
Multi-statute (no §101)2 (22%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
67% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
22% of docket
1
Business / Other
11% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

90 h
Manual time on pending OAs
18 h
Time saved (low, 20%)
31 h
Time saved (mid, 35%)
0.8 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NGUYEN, CAMTU TRAN 1 63.1% +38.9%
SAMALA, JAGADISHWAR RAO 1 67.9% +55.5%
LI, RUIXIANG 1 59.4% +19.1%
THOMAS, NATALIE NICOLE 1
MELCHIOR, JAMES RYLAND 1 62.1% +39.0%
LEONARD, ARTHUR S 1 50.9% +50.7%
LUO, JAMMY NMN 1
VIJAYARAGHAVAN, JAGAMYA NMN 1 60.0% +48.2%
MARVICH, MARIA 1 54.7% +27.9%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18706849 EXOSKELETON NGUYEN, CAMTU TRAN
17910530 METHOD FOR THE ANALYSIS OF GENETIC MATERIAL LUO, JAMMY NMN
17794087 LIPID NANOPARTICLES COMPRISING LESS THAN 1 MOL% OF A C18-PEG LIPID VIJAYARAGHAVAN, JAGAMYA NMN

Interview Candidates (7)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.

App #TitleExaminerDue in
17911041 A MIXTURE OF MRNA TO ENHANCE THE POTENCY OF DENDRITIC CELLS LEONARD, ARTHUR S 15d
18275986 SARBECOVIRUS BINDERS MELCHIOR, JAMES RYLAND 69d
18706849 EXOSKELETON NGUYEN, CAMTU TRAN
18697218 Fluorescently Labeled Immunoglobulin Single Variable Domains SAMALA, JAGADISHWAR RAO
18516777 Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof LI, RUIXIANG
17794087 LIPID NANOPARTICLES COMPRISING LESS THAN 1 MOL% OF A C18-PEG LIPID VIJAYARAGHAVAN, JAGAMYA NMN
17812951 Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof MARVICH, MARIA

Top Art Units

Art UnitApps
3786 1
1674 1
3774 1
1644 1
1631 1
1686 1
1633 1
1634 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18706849 EXOSKELETON NGUYEN, CAMTU TRAN 3786 §102§112 Non-Final OA Pending May 02, 2024
18697218 Fluorescently Labeled Immunoglobulin Single Variable Domains SAMALA, JAGADISHWAR RAO §103 Non-Final OA Pending Mar 29, 2024
18516777 Novel Antigen-Binding Chimeric Proteins and Methods and Uses Thereof LI, RUIXIANG 1674 §102 Non-Final OA Pending Nov 21, 2023
18289824 Improved Prosthesis, Exoskeleton, and Orthosis Devices and Method of Manufacturing Thereof THOMAS, NATALIE NICOLE 3774 §103 Non-Final OA 46d Pending Nov 07, 2023
18275986 SARBECOVIRUS BINDERS MELCHIOR, JAMES RYLAND 1644 §112 Non-Final OA 69d Pending Aug 04, 2023
17911041 A MIXTURE OF MRNA TO ENHANCE THE POTENCY OF DENDRITIC CELLS LEONARD, ARTHUR S 1631 §103Other Non-Final OA 15d Pending Sep 12, 2022
17910530 METHOD FOR THE ANALYSIS OF GENETIC MATERIAL LUO, JAMMY NMN 1686 §101§102§103§112 Non-Final OA Pending Sep 09, 2022
17794087 LIPID NANOPARTICLES COMPRISING LESS THAN 1 MOL% OF A C18-PEG LIPID VIJAYARAGHAVAN, JAGAMYA NMN 1633 §103§112 Final Rejection Pending Jul 20, 2022
17812951 Vectors for Liver-Directed Gene Therapy of Hemophilia and Methods and Use Thereof MARVICH, MARIA 1634 §112DP Non-Final OA Pending Jul 15, 2022

Managing Vrije Universiteit Brussel's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month